2025-05-07Niranjan Ghatule
Shares of Aarti Drugs surged 20% to hit the upper circuit at Rs 420 following strong Q4 FY24 results and favorable legal relief. The company reported a sharp rise in revenue and profit continues its Rs 600 crore capex-driven growth journey. With leadership in over 50 API molecules and a robust global footprint, Aarti Drugs is positioned for long-term expansion.
View more
Your experience on this site will be improved by allowing cookies
Cookie Policy
